Might be clearer to describe what is meant by "ADHD is diagnosed by subjective criteria…" What were the criteria? Just primary care doctor diagnosis?
Introduction: I am not familiar with the literature on GCs broadly, but are they called GCs both when taken as a prescription and when produced endogenously? If yes, that's fine, but it seems odd to describe that GC have anti-inflammatory properties and are taken as a prescription, then to describe them as a "stress hormone". Perhaps, note that when produced endogenously, they appear to take on the role of a stress hormone or similar phrasing.
The description of the fact that GCs have been shown to have adverse neurobehavioral outcomes in offspring is VERY vague. Like what? Why would the authors suspect that taking them as a prescription or if they were produced in excess endogenously would lead to ADHD specifically?
It also seems a bit short sighted to state that "causes of ADHD are unknown". While the sentiment is technically true, we do have a number of ideas regarding causal mechanisms and correlated mechanisms underlying the development of ADHD, including that it is roughly 70-% heritable.
The authors do go on to cite one study linking possible endogenous GC increase during the prenatal period to increased ADHD risk; however, the mechanism linking these two variables remains unclear, other than the authors note that GCs are passed through the BBB, etc.
Overall, the introduction would benefit from a bit more theory describing why one would expect or not expect GCs administered (or produced endogenously) during the prenatal period would be linked to ADHD in offspring.
Method: Methods appear appropriate. Was mother ADHD diagnosis obtained? Is there a correlation between the types of disorders that GC would be prescribed for and ADHD, such that mothers with ADHD would be more likely to use GC?
Statistical Analyses: Analyses appropriate. I particularly appreciate the sibling comparison cohort sample.
Results: Seem appropriate and well presented.
Discussion: Seems appropriate.
Minor:
In long form, according to both DSM 5 and APA, ADHD written out at length is attention-deficit/hyperactivity disorder.
I would have expected a table comparing characteristics of children with and without and ADHD diagnosis.
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GENERAL COMMENTS
This is a well-designed study and a well-written manuscript. The authors take advantage of a large, population-based register linkage to ensure excellent follow-up and generalizability of their results. The choice to present the population-level and sibling-comparison analyses together is commendable. The study question is relevant to the field, and the results are important to publish in that they will likely provide reassurance to pregnant women and their practitioners that continuing the recommended course of disease management for asthma and autoimmune disorders during pregnancy does likely pose additional risk to the neurodevelopment of the fetus. I have some suggestions to improve the manuscript (mostly to provide clarity), but, on the whole, I think that the manuscript is very deserving of publication.
Major comments:
1) A flow chart beginning with all births 1996-2009 and showing the number of children AND the number of mothers to those children included in the final analyses would be very useful to this study, even if included as a supplemental figure. It is clear that mothers can contribute more than one child to the final cohort (hence, the sibling design), though it is not clear how many mothers contributed children to this cohort. It is also not clear how the authors treated the missing maternal smoking data, or whether the crude and adjusted analyses include the same number of people (as they should). It is my experience in working with register data that a small percentage of children are missing paternal information, because the biological father is not identified in the register. Clearly defining the study population from the beginning would help the reader to understand how these missing values were handled. 2) Adding a column to Tables 4 specifying the number of cases and the number of unaffected individuals contributing to observations in each exposure category would also be helpful to the reader and provide greater information on the raw data contributing to the results of the statistical analyses. Similarly, breaking the first column of Table 5 into cases/unaffected would be useful. For example, if the prevalence of ADHD were 5% in the unexposed group in the sibling analysis, the authors could represent that as 75/1433 instead of specifying the total of 1508.
3) Since mothers can contribute more than one pregnancy to the cohort, using a sandwich estimator or similar method to estimate robust standard errors and thus account for the clustering of observations within the cohort (for the population-level/between mother analysis) would be appropriate.
4) The authors mention that BMI and marital status were considered in sub-analyses, but the results of these analyses aren't mentioned in the results section or shown in any supplementary tables. This ought to be corrected. The cut-offs used to define BMI categories in Table 3 should be specified.
5) The discussion would be improved with a more thorough discussion of the limitations of sibling comparison designs. These models have limitations of their own (see the work of Thomas Frisell and co-workers), and these limitations should be discussed (not just the issue of somewhat limited power).
6) The discussion would also be improved by a more thorough consideration of the mechanistic explanation of the results (i.e., the potential residual confounders of the population-level analysis). It's interesting that the authors see a bit of a "dose-response" relationship, in that those mothers with more than one systemic use of GCs had a higher HR for offspring ADHD compared to those with only one use. Paired with the results of the sibling comparison and the observed association with prior GC use, this gives more evidence for the "confounding by indication" hypothesis.
7) The authors could also do more to explore the potential for confounding by genetic factors (a real possibility, given the associations between autoimmune and atopic disorders and psychiatric disorders). In particular, it would be illuminating if the authors compared the risks associated with paternal use of GC during the same time periods as those compared with maternal GC use. A null result here could strengthen the "confounding by indication" hypothesis. A positive result would add evidence to the hypothesis of confounding by genetic factors. Results could be presented alongside the maternal results in Table 4 .
8) The authors mention that "environmental factors (breastfeeding, diet, second-hand smoke etc.)" could also be potential confounding factors. This language is vague and not very helpful in the discussion section. The authors should provide specific examples to clarify their thinking or drop this explanation entirely.
9) The sibling model need only need to be adjusted for factors that can vary between pregnancies. Since adjusting for parental psychiatric history before pregnancy is a proxy for genetic liability to psychiatric disorders, it's not necessary to include these variables in the sibling comparison analysis, even if there are a few cases when the parents seek treatment between pregnancies. A similar argument could be made for maternal diabetes, as it is formulated for this study (i.e., not including gestational diabetes). I would drop these co-variates from the sibling model. Also, calendar year of birth, birth order, and maternal age in the sibling model are likely to be highly co-linear. The authors need to explore this possibility, and likely drop at least one of these co-variates from their sibling comparison model.
Minor points 1) Table 4 : Label "Former users (unexposed)" as "Former users (unexposed during pregnancy)" 2) "Sex" would be a more precise term compared to "gender" for use in the tables and text.
3) Using a stratified Cox regression analysis for the sibling comparison would allow for a more direct comparison of the sibling results to the population-level results. The results would almost certainly be the same with either approach, and so I don't think that this is a necessary change. But it would spare the authors a few lines of text motivating the conditional logistic regression approach. 4) Move the last few sentences at the end of the "Sibling Comparison Cohort" subsection (Lines 27-32 on page 10) to the beginning of the statistical analysis section, since these sentences apply to all models. Answer: Thank you for this comment. We have re-worded the bullet point. Please see "Page 3, line 9-11".
VERSION 1 -AUTHOR RESPONSE

Introduction:
Comment: I am not familiar with the literature on GCs broadly, but are they called GCs both when taken as a prescription and when produced endogenously? If yes, that's fine, but it seems odd to describe that GC have anti-inflammatory properties and are taken as a prescription, then to describe them as a "stress hormone". Perhaps, note that when produced endogenously, they appear to take on the role of a stress hormone or similar phrasing. Answer: Thank you for pointing this out. We have re-written the introduction accordingly. Please see "Page "4-5". Comment: The description of the fact that GCs have been shown to have adverse neurobehavioral outcomes in offspring is VERY vague. Like what? Why would the authors suspect that taking them as a prescription or if they were produced in excess endogenously would lead to ADHD specifically? Answer: Excess GC exposure in utero (both exogenous and endogenous) has shown to be associated with adverse behavioural changes as well as increased anxiety levels. Also, maternal stress during pregnancy has been linked to ADHD in offspring which might be explained by excess endogenous GC. We have modified the introduction to make this clearer.
Comment: It also seems a bit short sighted to state that "causes of ADHD are unknown". While the sentiment is technically true, we do have a number of ideas regarding causal mechanisms and correlated mechanisms underlying the development of ADHD, including that it is roughly 70-% heritable. Answer: We agree. We have deleted that causes of ADHD are unknown and focused more on the heritability. Please see "Page 4, line 18-19" Comment: The authors do go on to cite one study linking possible endogenous GC increase during the prenatal period to increased ADHD risk; however, the mechanism linking these two variables remains unclear, other than the authors note that GCs are passed through the BBB, etc. Answer: We have specified that exogenous GC used in treatment regimens is absorbed into the blood stream and has thus the potential to affect human systems in the same way as endogenous GC (cortisol). Please see "Page 4" Comment: Overall, the introduction would benefit from a bit more theory describing why one would expect or not expect GCs administered (or produced endogenously) during the prenatal period would be linked to ADHD in offspring. Answer: We have modified the introduction. Please see "Page 4" Method: Methods appear appropriate. Comment: Was mother ADHD diagnosis obtained? Is there a correlation between the types of disorders that GC would be prescribed for and ADHD, such that mothers with ADHD would be more likely to use GC? Answer: Yes, data on maternal and paternal ADHD were obtained. This information is now separated from psychiatric illness in Table 3 . The ADHD diagnosis in parents with the same criteria as in the offspring (defined as a diagnosis of ADHD or by redemption of a prescription for ADHD medication). Autoimmune disease and psychiatric diseases have been linked. This is now added to the discussion, "page 12, line 6-7" Comment: This is a well-designed study and a well-written manuscript. The authors take advantage of a large, population-based register linkage to ensure excellent follow-up and generalizability of their results. The choice to present the population-level and sibling-comparison analyses together is commendable. The study question is relevant to the field, and the results are important to publish in that they will likely provide reassurance to pregnant women and their practitioners that continuing the recommended course of disease management for asthma and autoimmune disorders during pregnancy does likely pose additional risk to the neurodevelopment of the fetus. I have some suggestions to improve the manuscript (mostly to provide clarity), but, on the whole, I think that the manuscript is very deserving of publication. Answer: Thank you for your kind words as well as your good suggestions. We have made an effort to improve the manuscript. Major comments:
1) A flow chart beginning with all births 1996-2009 and showing the number of children AND the number of mothers to those children included in the final analyses would be very useful to this study, even if included as a supplemental figure. It is clear that mothers can contribute more than one child to the final cohort (hence, the sibling design), though it is not clear how many mothers contributed children to this cohort. It is also not clear how the authors treated the missing maternal smoking data, or whether the crude and adjusted analyses include the same number of people (as they should). It is my experience in working with register data that a small percentage of children are missing paternal information, because the biological father is not identified in the register. Clearly defining the study population from the beginning would help the reader to understand how these missing values were handled. Answer to comment 1: We have computed flow charts which are presented in the supplementary. As people with missing data (e.g. maternal smoking status) were very few (<5%), we handled missing data according to the "missing indicator" approach (Pedersen AB, et al. Missing data and multiple imputation in clinical epidemiological research. Clin Epidemiol. 2017 Mar 15; 9:157-166.).
2) Adding a column to Tables 4 specifying the number of cases and the number of unaffected individuals contributing to observations in each exposure category would also be helpful to the reader and provide greater information on the raw data contributing to the results of the statistical analyses. Similarly, breaking the first column of Table 5 into cases/unaffected would be useful. For example, if the prevalence of ADHD were 5% in the unexposed group in the sibling analysis, the authors could represent that as 75/1433 instead of specifying the total of 1508. Answer to comment 2: We have added the suggested information to Tables 4 and 5. 3) Since mothers can contribute more than one pregnancy to the cohort, using a sandwich estimator or similar method to estimate robust standard errors and thus account for the clustering of observations within the cohort (for the population-level/between mother analysis) would be appropriate. Answer to comment 3: Thank you. We have corrected this. 4) The authors mention that BMI and marital status were considered in sub-analyses, but the results of these analyses aren't mentioned in the results section or shown in any supplementary tables. This ought to be corrected. The cut-offs used to define BMI categories in Table 3 should be specified. Answer to comment 4: We apologize for this. The estimates did not change after adjusting for either BMI or marital status, which is now mentioned in the result section, please see "Page 11, line 8-9". The cut-offs used to define BMI categories in Table 3 have now been specified. 5) The discussion would be improved with a more thorough discussion of the limitations of sibling comparison designs. These models have limitations of their own (see the work of Thomas Frisell and co-workers), and these limitations should be discussed (not just the issue of somewhat limited power). Answer to comment 5: We have written a more thorough discussion of the limitations of the sibling design based on the recommended reference. Please see "Page 12, line 8-15". 6) The discussion would also be improved by a more thorough consideration of the mechanistic explanation of the results (i.e., the potential residual confounders of the population-level analysis). It's interesting that the authors see a bit of a "dose-response" relationship, in that those mothers with more than one systemic use of GCs had a higher HR for offspring ADHD compared to those with only one use. Paired with the results of the sibling comparison and the observed association with prior GC use, this gives more evidence for the "confounding by indication" hypothesis. Answer to comment 6: Yes, this is an interesting observation. We have extended the discussion according to the suggestions above. Please see "page 12, line 17-21". 7) The authors could also do more to explore the potential for confounding by genetic factors (a real possibility, given the associations between autoimmune and atopic disorders and psychiatric disorders). In particular, it would be illuminating if the authors compared the risks associated with paternal use of GC during the same time periods as those compared with maternal GC use. A null result here could strengthen the "confounding by indication" hypothesis. A positive result would add evidence to the hypothesis of confounding by genetic factors. Results could be presented alongside the maternal results in Table 4 . Answer to comment 7: We acknowledge this approach to investigate confounding by family related factors. However, we have chosen the former user analysis to support the sibling design.
8) The authors mention that "environmental factors (breastfeeding, diet, second-hand smoke etc.)" could also be potential confounding factors. This language is vague and not very helpful in the discussion section. The authors should provide specific examples to clarify their thinking or drop this explanation entirely. Answer to comment 8: We have deleted this explanation entirely.
9) The sibling model need only need to be adjusted for factors that can vary between pregnancies. Since adjusting for parental psychiatric history before pregnancy is a proxy for genetic liability to psychiatric disorders, it's not necessary to include these variables in the sibling comparison analysis, even if there are a few cases when the parents seek treatment between pregnancies. A similar argument could be made for maternal diabetes, as it is formulated for this study (i.e., not including gestational diabetes). I would drop these co-variates from the sibling model. Also, calendar year of birth, birth order, and maternal age in the sibling model are likely to be highly co-linear. The authors need to explore this possibility, and likely drop at least one of these co-variates from their sibling comparison model. Answer to comment 9: We have omitted parental psychiatric disease, diabetes and maternal age. Please see Table 5 on page 19.
Minor points 1) Table 4 : Label "Former users (unexposed)" as "Former users (unexposed during pregnancy)" Answer to comment 1: We have changed the label as suggested.
2) "Sex" would be a more precise term compared to "gender" for use in the tables and text. Answer to comment 2: We have changed the word gender to sex throughout the manuscript.
3) Using a stratified Cox regression analysis for the sibling comparison would allow for a more direct comparison of the sibling results to the population-level results. The results would almost certainly be the same with either approach, and so I don't think that this is a necessary change. But it would spare the authors a few lines of text motivating the conditional logistic regression approach. Answer to comment 3: We have changed the analysis to the stratified cox-regression to allow for a more direct comparison to the population-level analyses. This has not changed the conclusion of no association in the sibling design. 4) Move the last few sentences at the end of the "Sibling Comparison Cohort" subsection (Lines 27-32 on page 10) to the beginning of the statistical analysis section, since these sentences apply to all models. Answer to comment 4: We have moved the sentence to the beginning of the section.
